Amended Statement of Ownership (sc 13g/a)
February 12 2018 - 11:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of
1934
(Amendment No. 2)*
Protalix Biotherapeutics,
Inc.
(Name of Issuer)
Common Stock,
$0.001 par value per share
(Title of Class of
Securities)
74365A101
(CUSIP Number)
December 31,
2017
(Date of Event Which
Requires Filing of this Statement)
Check the appropriate box to designate
the rule pursuant to which this Schedule is filed:
*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
CUSIP
No.
74365A101
1.
|
Names
of Reporting Persons.
Nineteen77
Global Multi-Strategy Alpha Master Limited
|
2
.
|
Check
the Appropriate Box if a Member of a Group (See Instructions)
(a)
☐
(b)
☐
|
3
.
|
SEC
Use Only
|
4
.
|
Citizenship
or Place of Organization
Cayman
Islands
|
Number
of
shares
Beneficially
O
wned by
E
ach
R
eporting
person
with
:
|
5
.
|
Sole
Voting Power
0
|
6
.
|
Shared
Voting Power
8,937,333
|
7
.
|
Sole
Dispositive Power
0
|
8.
|
Shared
Dispositive Power
8,937,333
|
9
.
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
8,937,333
(see Item 4)
|
10
.
|
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
☐
|
11
.
|
Percent
of Class Represented by Amount in Row (9)
6.0
%
(see Item 4)
|
12
.
|
Type
of Reporting Person (See Instructions)
CO;
OO
|
This Amendment No. 2
is being filed by the Reporting Person and amends the Schedule 13G initially filed by the Reporting Person with the Securities
and Exchange Commission (the “
SEC
”) on February 15, 2017, as amended by Amendment No. 1 thereto filed by the
Reporting Persons with the SEC on February 15, 2017 (the “
Schedule 13G
”).
Except as set forth
below, all Items of the Schedule 13G remain unchanged. All capitalized terms not otherwise defined herein shall have the meanings
ascribed to such terms in the Schedule 13G.
Item 2.
(a) Name of Person Filing
(b) Address of Principal Business Office or, if none,
Residence
(c) Citizenship
The Reporting
Person changed its name from O’Connor Global Multi-Strategy Alpha Master Limited to Nineteen77 Global Multi-Strategy Alpha
Master Limited.
Item 4.
Ownership.
(a) and (b):
As
of the close of business on December 31, 2017
,
the Reporting Person may have been deemed
to have beneficial ownership of 8,937,333 shares of Common Stock issuable upon conversion of a convertible note held by the Reporting
Person (the “
Note
”), and all such shares of Common Stock represented beneficial ownership of approximately
6.0% of the Common Stock, based on (1)
139,727,673 shares of Common Stock outstanding as of November 1, 2017, as reported
in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2017 filed with the SEC on November
8, 2017, plus (2)
8,937,333 shares of Common Stock issuable upon conversion of the Note
.
(c)
(1) Sole power to vote or to direct the vote:
0
.
(2) Shared power to vote or to direct the vote:
8,937,333
.
(3) Sole power to dispose or to direct the disposition
of
0
.
(4) Shared power to dispose or to direct the disposition
of
8,937,333
.
Item 10. Certification
By signing below I
certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the
purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and
are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely
in connection with a nomination under §240.14a-11.
SIGNATURE
After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 12, 2018
|
Nineteen77 Global Multi-Strategy Alpha Master Limited
|
|
|
|
|
By:
|
UBS O’Connor
LLC, its investment advisor
|
|
|
|
|
By:
|
/s/ Nicholas
Vagra
|
|
|
Name: Nicholas
Vagra
|
|
|
Title: Manager,
Chief Operating Officer
|
|
|
|
|
By:
|
/s/ Andrew
Hollenbeck
|
|
|
Name: Andrew
Hollenbeck
|
|
|
Title: General
Counsel
|
Page 4 of 4
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Sep 2023 to Sep 2024